We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

The companies Eikon Therapeutics, Sionna Therapeutics, and Abcuro bagged the biggest biotech funding rounds overall in ...

The company also represents Advancell expandable microspheres, and S-LEC BK polyvinyl acetal resins. Sekisui Specialty ...

Its licensing agreement with Australian startup AdvanCell was revealed two weeks ago. Leveraging AdvanCell’s Pb-212 production technology and radionuclide development infrastructure and Eli Lilly’s ...

bluebird stockholders to receive $3.00 per share in cash and a contingent value right of $6.84 per share in cash payable upon achievement of a net sales milestone, contingent upon offer conditions ...

AdvanCell, a clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, today announced the successful completion of an oversubscribed US$112 million Series C financing.

Johnson Winter Slattery (JWS) has assisted three of the lead investors in AdvanCell’s US$112m Series C financing effort. The firm worked with SV Health Investors, Sanofi Ventures and Abingworth on the ...

AdvanCell has raised an oversubscribed US$112 million ($178.6 million) Series C round, enticing investors with its plan to produce cutting-edge nuclear medicines and novel cancer treatments.

Prostate Cancer Real World Evidence Registry (PROCARE): Recurrent and metastatic prostate cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This abstract ...

Brisbane-based AdvanCell raised $178 million in one of the biggest funding rounds of 2025 so far. It's good news for an overlooked corner of the startup sector. AdvanceCell CEO Andrew Adamovich and ...

Parliament has passed the Scam Prevention Framework bill, a first-of-its-kind legislation aimed at curbing financial scams and enhancing protections across key industries. The bill establishes ...

Novartis agreed to a deal worth up to $3.1 billion for Blackstone Life Sciences’ Anthos Therapeutics. Merck KGaA confirmed that it is in talks to acquire SpringWorks Therapeutics, though a deal has ...